Position of the Transparency Council – Livmarli (maralixibat)

At its meeting on 11 July 2022 the Transparency Council adopted Position No. 63/2022 on the legitimacy of granting reimbursement approval for the medicinal product Livmarli (maralixibat) for the indication: pruritus of the skin in Alagille syndrome.